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Background: Pneumonia is a leading cause of childhood mortality globally. Oxygen therapy improves survival in
children with pneumonia, yet its availability remains limited in many resource-constrained settings where most
deaths occur. Solar-powered oxygen delivery could be a sustainable method to improve oxygen delivery in remote
areas with restricted access to a supply chain of compressed oxygen cylinders and reliable electrical power.
Methods/Design: This study is a randomized controlled trial (RCT). Solar-powered oxygen delivery systems will be
compared to a conventional method (oxygen from cylinders) in patients with hypoxemic respiratory illness. Enrollment
will occur at two sites in Uganda: Jinja Regional Referral Hospital and Kambuga District Hospital. The primary outcome will
be the length of hospital stay. Secondary study endpoints will be mortality, duration of supplemental oxygen therapy
(time to wean oxygen), proportion of patients successfully oxygenated, delivery system failure, cost, system maintenance
and convenience.
Discussion: The RCT will provide useful data on the feasibility and noninferiority of solar-powered oxygen delivery. This
technological innovation uses freely available inputs, the sun and the air, to oxygenate children with pneumonia, and can
be applied “off the grid” in remote and/or resource-constrained settings where most pneumonia deaths occur. If proven
successful, solar-powered oxygen delivery systems could be scaled up and widely implemented for impact on global
child mortality.
Trial registration: Clinicaltrials.gov registration number NCT0210086 (date of registration: 27 March, 2014)
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Pneumonia is a leading cause of pediatric mortality glo-
bally, causing 0.9 million deaths/year [1]. Countries in
Africa and Asia report two to 10 times more cases of
pneumonia than industrialized countries like the USA,
and the majority of pneumonia deaths [2–4]. Respiratory
distress and hypoxemia are presenting features of life-
threatening bacterial pneumonia, as well as pulmonary
tuberculosis, sepsis and severe malaria. These common
and treatable infections lead to hypoxemia as a final
common pathway, for which oxygen (O2) therapy is an
essential supportive therapy.* Correspondence: mthawkes@ualberta.ca
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creativecommons.org/publicdomain/zero/1.0/Large gaps remain in the case management of children
presenting to African hospitals with respiratory distress,
including supplemental oxygen. A 2012 survey found
that only 44 % of 231 health centers, district hospitals,
and provincial/general hospitals in 12 African countries
had access to oxygen on a continuous basis [5]. In
Malawi in 2008, oxygen was not available in four out of
five district hospital pediatric wards visited, and health
workers did not know when or how to administer oxy-
gen to children [6]. Similarly, in another survey, oxygen
was not available for 13 % of hypoxemic children admit-
ted to five hospitals in New Guinea [7]. However, im-
proved oxygen delivery systems can lead to measurable
improvements in survival. A multihospital effectiveness
study in Papua New Guinea demonstrated a reduction
in mortality from childhood pneumonia from 5.0 % to
3.2 % (35 % reduction in mortality) after implementationarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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oxygen concentrators and training) [8].
Current methods commonly used to deliver hospital
oxygen in resource-limited settings include compressed
oxygen cylinders and oxygen concentrators. Cylinders
require a reliable supply chain linking the oxygen pro-
duction plant to the hospital, which may be compro-
mised by poor road conditions, costs of transportation
and weak stock management. Furthermore, while cylinders
themselves are robust, tank regulators, used to deliver a
constant and metered flow of oxygen, are frequently ill fit-
ting and poorly maintained, resulting in substantial gas leak
and waste of compressed oxygen. Oxygen concentrators
represent a significant technological advance, purifying oxy-
gen from ambient air through selective adsorption of nitro-
gen using aluminum silicate sieve beds. However, these
require a constant uninterrupted electrical supply, which
may not be available in resource-poor settings. We propose
a novel strategy for oxygen delivery that could be imple-
mented in remote locations with minimal access to oxygen
cylinders or an electrical power supply: solar-powered oxy-
gen (SPO2) delivery. Here, we describe the protocol for aFig. 1 Trial flow diagram. *The trial capacity is two beds with a concentrator an
same arm, subsequent patients were not enrolled because of the potential inabrandomized controlled trial (RCT) to compare SPO2 to
conventional oxygen delivery from cylinders.
Methods/Design
Study design
The study is a prospective, randomized, controlled clin-
ical trial comparing solar-powered oxygen delivery to
oxygen in compressed cylinders in children under 13
years of age admitted with hypoxemic respiratory illness.
The patient flow diagram is shown in Fig. 1.
Study objectives
The overall objective is to demonstrate the noninferiority of
solar-powered oxygen delivery relative to standard oxygen
delivery. Specifically, we will compare the length of stay in
children hospitalized with acute hypoxic respiratory illness
randomized to SPO2 versus cylinder oxygen. The working
hypothesis is that the length of stay is not increased in chil-
dren treated with SPO2 compared to children receiving cy-
linder oxygen. Secondary outcomes will be compared
between groups, including patient-specific outcomes
(mortality, duration of supplemental oxygen therapyd two beds with a cylinder. In case of two patients already enrolled in the
ility to randomize to the occupied beds
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oxygenated, and clinical severity scores) and oxygen de-
livery system indicators (system failures, cost, mainten-
ance and convenience of use).Eligibility criteria
Inclusion criteria
Inclusion criteria include the following:
1. Age <13 years
2. Integrated Management of Childhood Illness (IMCI)
defined severe pneumonia or very severe disease [9]
3. Hypoxemia (peripheral saturation<90 %) based on
noninvasive pulse oximetry
4. Hospital admission warranted based on clinician
judgment
5. Consent to blood sampling and data collectionExclusion criteria
Exclusion criteria include the following:
1. Outside eligible age range
2. Peripheral oxygen saturation ≥90 %
3. Suspected pulmonary tuberculosis
4. Outpatient management
5. Denial of consent to participate in study
6. Trial inpatient capacity exceeded
The reason for exclusion of patients with pulmonary
tuberculosis is for infection control, in order to avoid
the risk of transmitting tuberculosis to other patients
housed in the study unit. The trial inpatient capacity at
each study site is two beds with a concentrator and two
beds with a cylinder. In cases where two patients are
already enrolled in the same arm, subsequent patients
will not be enrolled because of the potential inability to
randomize to the occupied beds.Study setting
The trial will take place at two hospitals in Uganda: (1)
the Jinja Regional Referral Hospital is located in in mid-
eastern Uganda, which serves a large catchment area in
the Busoga Region, and (2) Kambuga Hospital in Western
Uganda, a remote site with limited road access. Both are se-
verely resource-limited hospitals with inconsistent electrical
power supply, and both were using oxygen from cylinders
and concentrators at the time of study planning. Uganda
has a high burden of child mortality and pneumonia: the
under-five mortality rate in 2008 was 135 deaths per 1000
(19th highest rate worldwide), and pneumonia is the
fourth leading cause of mortality in Ugandan children
under five (11 %) [1].Treatment groups
Children will be randomly assigned to receive oxygen
using either SPO2 or cylinder oxygen in a 1:1 ratio.
The intervention arm is oxygen from a solar-powered
concentrator. The SPO2 systems, which are built in Jinja
and Kambuga, consist of photoelectric panels (80 W or 175
W panels, Solarworld, Freiburg, Germany), charge con-
troller (FLEXmax 80, OutBack Power, Arlington, WA,
USA or 40 A/24 V Controller, Steca Elektronik GmbH,
Memmingen, Germany), bank of gel batteries (220 Ah/12
V UltraPower gel batteries, Victron Energy BV, Almere
Haven, The Netherlands), power inverter (3000 VA/48 V
Inverter/Charger or 1600 VA/24 V Inverter/Charger,
Victron Energy BV, Almere Haven, The Netherlands)
and oxygen concentrator (model 525 KS, DeVilbiss
Healthcare LLC, Somerset, PA, USA). The system is de-
signed to run independently of hydroelectric power
source (exclusively driven by solar energy), and provide
continuous uninterrupted oxygen (up to 5 L/min)
throughout both day and night (using energy stored in
battery bank). The total cost of each system was ap-
proximately US $18,000.
The control arm consists of oxygen in a cylinder with
flow regulator, tubing and nasal prongs or mask for de-
livery to the patient. Cylinders (pressure, capacity) can
be purchased from commercial suppliers in Uganda
(Oxygas, Kampala, Uganda) at a cost of US $200 and are
refillable at a cost of US $14. In addition, a regulator
(US $200) is needed. On average, one pediatric patient
with pneumonia will consume approximately 1-6 cylin-
ders of oxygen during the course of hospitalization for
pneumonia. In order to have a reliable supply of oxy-
gen, given procurement and transport times, we esti-
mate that six cylinders need to be stocked on the
hospital premises.
Randomization method
Block randomization by study site will be employed,
using a computer-generated list. Treatment allocation
will be kept in sequentially numbered, sealed, opaque
envelopes, which will be drawn for each randomized
participant. We will retain all envelopes and records for
quality-monitoring purposes.
Outcome measures
Length of stay will be the primary outcome. A standardized
and objective decision rule will be used for hospital dis-
charge. All of the following criteria will be required for
discharge: (1) off oxygen for at least 24 hours (requires
saturation ≥90 % on room air); (2) absence of fever for
24 hours; (3) vital signs stable; and (4) drinking and/or
breastfeeding well.
Several secondary outcomes will be recorded. Patient-
specific outcomes will be measured in each group:
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duration of oxygen therapy, and clinical severity score.
The proportion of patients successfully oxygenated will
be defined as the number of patients who achieve a satur-
ation ≥90 % for ≥12 hours after initiating oxygen therapy.
The clinical severity scores used will be the previously
published and validated Lambaréné Organ Dysfunction
Score (LODS) [10] and the Respiratory Index of Severity
in Children (RISC) [11].
Oxygen delivery system variables will include direct
costs (capital investment, operating costs, system main-
tenance, etcetera), details of maintenance needs, con-
venience of use of the systems and proportion of
patients for whom the delivery system failed. System fail-
ure will be defined as inadequate oxygen production to
meet patient needs for any reason. Examples would in-
clude battery failure for SPO2 or out-of-stock cylinder
oxygen.Safety
Oxygen therapy is known to be a life-saving interven-
tion, and this study will improve hospital capacity for
the treatment of hypoxemic children. While patients will
be randomized to one of two possible oxygen delivery
systems, there are no risks, and benefits include poten-
tially life-saving access to oxygen, regardless of delivery
modality. Study participants will be managed at the Jinja
Regional Referral Hospital according to national guide-
lines and local clinical practices. Outcome assessment in
the study will not pose any risk to the study participants.
Adverse events, defined according to Good Clinical
Practice (GCP) guidelines as any untoward event occur-
ring in a study participant, will be logged prospectively
and tabulated at the end of the study, disaggregated by
study arm. Severe adverse events, defined as those ad-
verse events that prolong hospitalization or lead to per-
manent disability or death, will be reported to regulatory
authorities in an expedited manner and reported separ-
ately in the safety analysis.
This study involves hypoxemic patients with severe
pneumonia or very severe disease, and the mortality is
expected to be high because of the underlying illness.
Mortality among patients receiving SPO2 will to be
interpreted in comparison to patients receiving O2 by
standard method (cylinders).Ethical considerations
The Makerere University School of Biomedical Sciences
Research and Ethics Committee (SBS-REC, # SBS 139),
together with the University Health Network Research
Ethics Board (UHN REB, # 13-6168-AE) of the Univer-
sity of Toronto have reviewed and approved the study
protocol. The Uganda National Council on Science andTechnology (UNCST, # SS 331) has also approved the
study.
Written informed consent will be obtained from the
caregivers of all children that will participate in the
study. The consent has been translated into local lan-
guages (Luganda, Lusoga and Rukiiga). Illiteracy is com-
mon in the study area, requiring adaptation of the
consent process. For those who do not know how to
read and write, an independent witness will be present
during the informed consent process and will sign the
consent form as a witness. The parent themselves will
affix a thumbprint to the consent form. Assent will be
solicited for patients above 8 years of age.
Sample size calculations
We will enroll a total of 130 patients. This sample size
was calculated as follows. A 1:1 ratio of patients will be
assigned to SPO2 or control (cylinder O2). We consider
a 1-day prolongation of hospital stay to be clinically sig-
nificant (noninferiority margin). Using pilot data from a
prospective study at Jinja Regional Referral Hospital, 69
patients with hypoxic pneumonia had a mean (standard
deviation) length of stay of 2.6 (2.1) days (unpublished
data). By standard calculations for normally distributed
data, 57 patients in each group will provide 80 % power
to demonstrate noninferiority of SPO2 relative to oxygen
by cylinder at α = 0.05 (one-sided). This sample size was
increased by 15 % to account for a probable non-
Gaussian distribution of the data [12].
Primary analysis
Length of stay (in days) will be coded as a whole number
(continuous variable). Difference in length of stay between
groups will be compared using the nonparametric method
of Hodges and Lehman. If the a priori noninferiority mar-
gin (Δ = 1 day) is below the lower limit of the 95 % confi-
dence interval for the median of differences, the trial will
conclude that SPO2 is noninferior to cylinder oxygen. In
order to account for all patients randomized (“intention-to-
treat” analysis), we will perform sensitivity analyses to ac-
count for missing data due to mortality, study withdrawal,
and transfer to another facility. A per protocol population
(non-fatal cases discharged home from hospital) will be
used to assess the robustness of the primary result
(non-inferiority). Details of the sensitivity analyses will
be included in a Statistical Analysis Plan, which will be
closed as early as possible in the conduct of the trial.
Secondary outcomes
The mortality will be compared between groups using
the chi-squared statistic, or Fisher’s exact test, as appro-
priate. The proportion of patients successfully oxygen-
ated and proportion of patients for whom the oxygen
delivery system failed will be analyzed in a similar
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using nonparametric methods (Mann-Whitney U-test)
and/or Cox-proportional hazard models. Costs will be care-
fully tabulated (capital investment, ongoing costs, and sys-
tem maintenance, etcetera) and summarized for each group
of patients. Details of maintenance needs and convenience
of use of the systems will be documented and tabulated.
The LODS and RISC (clinical severity scores) will be
assessed and recorded serially over the course of hospital
admission; comparison between groups will make use
of linear mixed effects models to compare the longitu-
dinal time course of the clinical severity score during
convalescence.
Discussion
Our protocol describes a randomized controlled trial to
test the hypothesis that solar-powered oxygen delivery is
noninferior to standard methods (oxygen from cylinders)
for the supportive care of children with hypoxemia and
respiratory distress. Demonstrating the utility of this
technological innovation will represent an important
step toward scale-up and implementation of reliable oxy-
gen delivery in remote and resource-limited hospitals.
The principle of the solar-powered oxygen delivery
system relies on two existing technologies, photoelectric
panels and oxygen concentrator, to yield a stream of
oxygen that requires only sun and air as inputs. Existing
oxygen concentrators use pressurized beds of aluminum
silicate to adsorb nitrogen from ambient air, generating
relatively pure oxygen (up to 95 %). Using solar energy
to power the concentrator allows it to operate in settings
where the supply of electricity is unreliable. Previous
studies have described the clinical use of oxygen concentra-
tors in developing countries [6, 13–15], but, to our know-
ledge, only one narrative report to date from the Gambia
has described a solar-powered oxygen system (design and
cost), and clinical data were not reported [16].
Noteworthy aspects of this trial include its setting in
two severely resource-limited hospitals, where hypoxemic
patients do not have reliable access to oxygen, intensive
care environment, endotracheal intubation, or mechanical
ventilatory support. This situation is common across hos-
pitals in sub-Saharan Africa [5], and contributes to ele-
vated mortality rates from pediatric pneumonia. Threats
to consistent oxygen supply in our centers and others in-
clude weak supply chain for oxygen cylinders, inconsistent
electric power supply, and lack of well-maintained oxygen
concentrators. The use of solar-powered oxygen elimi-
nates the need for oxygen cylinders and electricity but will
still require minimal equipment maintenance. The study
setting in equatorial Uganda is also representative of many
African sites, where solar energy is abundant and can be
harnessed for oxygen purification from ambient air. Our
trial will provide “real-life” data on system operation underfield conditions including variability in sun intensity
throughout the day and with weather conditions (energy
available) and patient oxygen demands. These features in-
crease the generalizability of our findings to similar set-
tings and will inform future refinements and optimization
of the solar-powered oxygen delivery system.
One limitation of this study is the lack of blinding.
Given the nature of the intervention (oxygen concentra-
tor or cylinder), it is not feasible to blind clinicians or
participants to the intervention in our setting. Decisions
about the primary outcome (length of stay) are subject
to clinician judgment, opening the possibility of bias. To
mitigate this potential bias, we will use objective criteria
for hospital discharge, which will be applied uniformly
to patients in both arms. We have chosen length of stay
(continuous variable), rather than mortality as the primary
study endpoint for pragmatic reasons. The binary outcome
mortality would require a much larger and costlier study to
show noninferiority (sample size of n = 1,134 per group
needed to show noninferiority within a margin of 5 % abso-
lute risk difference). For the sample size calculation, we
used a one-sided 5 % significance level, rather than the
more conventional two-sided approach. This reduced the
total sample size by approximately 30 patients while still
permitting demonstration of noninferiority with 95 % confi-
dence (based on the lower limit of the one-sided confidence
interval).
Several potential confounding factors may impact our
primary outcome (length of stay) or secondary outcomes
(for example, mortality) among patients with hypoxemia.
These include host factors (for example, patient age,
underlying immune deficiency like HIV), disease-specific
factors (for example, pathogen and severity of infection),
and co-treatments (for example, antibiotics). Our ran-
domized design is expected to distribute these variables
equally between study arms, and we have not attempted
to stratify the cohort due to the modest sample size. Sec-
ondary analyses (for example, multivariable regression)
may be undertaken to explore the important predictors
of patient outcomes in this cohort.
Potential impacts of solar-powered oxygen delivery in-
clude a reduction in pneumonia-specific and overall
child mortality if this technology can be brought to scale
and implemented widely in Africa and Asia. Toward this
goal, our RCT will provide strong empirical data to sup-
port the feasibility and noninferiority of SPO2 in
resource-limited African hospitals. We anticipate that
this trial will also provide valuable data for future design
and refinement of solar-powered oxygen delivery sys-
tems, including the potential for commercial develop-
ment. A significant reduction in the number of children
dying of pneumonia may be realized with this pragmatic
method to provide supportive therapy with oxygen
globally.
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Recruitment of study participants ongoing.
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